Shire posts 16 pct rise in full-year earnings, sees slower growth in 2018
LONDON, Feb 14 (Reuters) - Shire (Xetra: S7E.DE - news) , the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.
The London-listed company on Wednesday reported full-year revenue of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per ADS of $15.15, which came in towards the top of its guidance.
(Reporting by Paul Sandle; editing by James Davey)